Teva’s Ascent Faces Mounting Skepticism

Teva US8816242098

Pharmaceutical giant Teva is experiencing a remarkable surge in its share price, yet a growing chorus of doubters is emerging just as the stock approaches record levels. While recent regulatory approvals in Europe are fueling the growth narrative, a notable increase in short-selling activity is signaling underlying market concerns.

The company’s trajectory recently encountered a hurdle in the United States. A federal court dismissed Teva’s lawsuit challenging the Medicare drug price negotiation program. The company had contended that the initiative infringed upon its property rights for medications such as Austedo.